Lawmakers and medical cannabis advocates gathered at Mercer University in Macon to debate broadening Georgia's decade-old medical cannabis program. The discussion highlights tensions between patient needs and policy caution amid calls to increase THC potency. With over 33,000 approved patients relying on low-THC oil, expansion could address gaps but risks hasty changes.
Georgia's Limited Medical Cannabis Framework
Georgia legalized medical cannabis in 2015, restricting it to low-THC oil for specific conditions. The state now supports more than 10 dispensaries, but production lags with only three operating facilities, including Fine Fettle in Macon. This setup serves 33,000 patients yet falls short of diverse product options available elsewhere.
Lawmakers Advocate Measured Progress
Representative Mark Newton emphasized the study committee's role in deliberate policymaking after a decade of operation. He urged in-depth review to avoid rushed decisions on access. Representative Robert Dickey acknowledged benefits for patients but noted slow advancement, attributing delays partly to limited prior medical research due to federal restrictions.
Industry Seeks Higher THC Limits
Fine Fettle President Judson Hill pressed lawmakers to raise THC percentages, arguing Georgia's program hinders patients. He pointed out that 40 states offer medical cannabis with stronger products, leaving Georgia behind. Advocates argue current limits deny necessary access and strength for those in need.
Implications for Patient Access Nationwide
Expansion could align Georgia with most states, easing suffering for qualifying patients through varied formulations. Yet federal illegality continues to constrain research, slowing evidence-based reforms. The Mercer forum signals potential shifts, balancing caution with demands for equitable care in a patchwork national landscape.
